Similar Search Results

The Promise to the Public : Generic Competition: Submission to the Pharmaceutical Patents Review

Moir, Hazel V. J. - 2014

This submission takes a public policy perspective, focusing on the public return from the patent system through competition based on the new technology after the 20-year patent monopoly period expires. The government has agreed time-limited monopolies to encourage domestic invention (the patent...

Persistent link: https://www.econbiz.de/10014149017

Competition and the efficiency of markets for technology

Allain, Marie-Laure; Henry, Emeric; Kyle, Margaret K. - In: Management science : journal of the Institute for … 62 (2016) 4, pp. 1000-1019

Persistent link: https://www.econbiz.de/10011460538

Competition, technology licensing-in, and innovation

Moreira, Solon; Klueter, Thomas Maximilian; Tasselli, … - In: Organization science : a journal of the Institute for … 31 (2020) 4, pp. 1012-1036

Persistent link: https://www.econbiz.de/10012294915

Pharmaceutical patents and generic entry competition : a new view on the Hatch-Waxman Act

Wan, Yunyun; Miyagiwa, Kazuyuki - 2015

Persistent link: https://www.econbiz.de/10011349854

Pay-for-delay patent settlement, generic entry and welfare

Ding, Yucheng; Zhao, Xin - In: International journal of industrial organization 67 (2019), pp. 1-18

Persistent link: https://www.econbiz.de/10012321579

Reaching for Mediocrity : Competition and Stagnation in Pharmaceutical Innovation

Le, Son; Sukhatme, Neel U. - 2021

We model how risk-neutral firms’ ability to obtain substantial private returns on marginal new technologies causes them to "reach for mediocrity" by investing in socially suboptimal projects, even in the presence of competition and new entrants. Focusing primarily on pharmaceutical innovation,...

Persistent link: https://www.econbiz.de/10013251136

Does Regulation Drive Out Competition in Pharmaceutical Markets?

Danzon, Patricia M.; Chao, Li-Wei - 2011

Most countries regulate pharmaceutical prices, either directly or indirectly, on the assumption that competition is at best weak in this industry. This paper tests the hypothesis that regulation of manufacturer prices and of retail pharmacy margins undermines price competition. We use data from...

Persistent link: https://www.econbiz.de/10014038394

Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany

Herr, Annika; Suppliet, Moritz - 2012

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to … (no. of firms) suggests a significant but small negative correlation with prices. -- pharmaceuticals ; prices ; co …

Persistent link: https://www.econbiz.de/10009522774

Free Movement and Competition in the European Market for Pharmaceuticals

Caro de Sousa, Pedro - 2016

.This chapter will provide an overview of free movement cases on pharmaceuticals, with a view to frame such case law within the … section will provide an overview of the structure of the European market for pharmaceuticals, including the basic European … regulatory framework; a second section will review the case law on free movement and pharmaceuticals; and a last section will …

Persistent link: https://www.econbiz.de/10012980141

Double Patenting : Follow-On Pharmaceutical Patents that Suppress Competition

Rogers, Douglas L. - 2016

Prices for pharmaceutical products over the last 10 years have skyrocketed, increasing far more rapidly than the general cost of living. This article argues there should be greater competition for the production of follow-on drugs through the strengthening of the double patenting prohibition:...

Persistent link: https://www.econbiz.de/10013002400

1
2
3
4
5
6
7
8
9
10
Next
Last